News 23.09.19

Citryll collaborates with leading NET researcher Dr. Markus Hoffmann

Oss, The Netherlands, Erlangen, Germany September 18, 2019 —http://www.citryll.com/ announced today that it has established a collaboration with Dr. Markus...

Read more
News 18.09.19

GLYCOSTEM signs two commercialisation agreements with Korean partner

OSS, Netherlands — On 9 September 2019 Glycostem and an undisclosed Korean partner confirmed the signing of two agreements. The...

Read more
News 11.09.19

Pivot Park welcomes LifeScience@Work Venture Challenge bootcamp

The LS@W Venture Challenge is a 10-week programme to develop an initial idea – a breakthrough research result – into...

Read more
News 24.07.19

Osteo-Pharma Release: Successful Preclinical Dental defect study Demonstrates Enhanced Bone Regeneration Properties of OsteoActivator coated collagen membranes

Osteo-Pharma, a Dutch Life Sciences company developing novel pharmaceuticals and medical devices to improve the local healing of bone fractures and defects, today has announced that it has successfully completed a large preclinical study in mini-pigs, which shows its OsteoActivator coated collagen membranes to effectively promote new bone formation.

Read more
News 04.07.19

“I liked academic work, but after my PhD I did not aspire to an academic career: I wanted to broaden my horizons.”

BioConnection, a spin-off of MSD/Organon, has undergone rapid development in recent years: from a consultant/broker without its own facilities to a production company that offers its Drug Product related services to medium-sized pharmaceutical players worldwide. The core business is the filling of medicines in various forms under GMP, mostly in vials and syringes. BioConnection works for customers at Pivot Park, but also globally for pharmaceutical companies in, amongst others, US, Europe, Australia, Brazil, Israel, , Korea and Taiwan.

Read more
News 25.06.19

Glycostem’s mission to manufacture NK cells from cord blood stem cells and treat cancer patients could play a pivotal role in combating this deadly disease.

Glycostem develops innovative therapies for the treatment of different types of cancer: leukaemia, lymphoma and solid cancers. It is an off-the-shelf immune therapy, in which so-called Natural Killer Cells play an important role. John Veluchamy focuses on the development of affordable, highly effective, off-the-shelf therapy against tumours. His research into NK cells, derived from the umbilical cord, plays an important role in this. Veluchamy comes from India, studied Biomedical and Molecular Sciences at King’s College in London and obtained his PhD in NK cell immunotherapy from VU University Amsterdam in 2018. He has been working full time at Glycostem since December 2016. Veluchamy sees a major role for the Netherlands in the development of new medicines. The arrival of the European Medical Agency will consolidate this role.

Read more
News 12.06.19

Calquence Phase III ELEVATE-TN trial met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia

Calquence alone or in combination significantly increased the time patients lived without disease progression AstraZeneca announced positive results from the...

Read more
News 03.06.19

A cup of coffee with…Robin Voets (Acerta Pharma)

Robin started in 2017 as an intern at Acerta Pharma. "During my internship I synthesized a tool compound for the validation of the biology of the target we were working on at the time and for comparative studies with new compounds to determine in what way the compounds differentiate themselves."

Read more
News 29.05.19

Synaffix Announces 3rd License Taken by ADC Therapeutics

Synaffix B.V., a Dutch biotechnology company focused on the advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development...

Read more